Tag
This study reveals mycophenolate and azathioprine do not improve 3-year transplant-free survival or lung function in fibrotic ILD, with potential harm in select subtypes. Robust randomized trials remain essential for guiding immunosuppressi
The 2026 international report redefines acute exacerbation across fibrotic interstitial lung diseases, proposes a framework to separate AE from other acute respiratory worsenings, and sets priorities for diagnosis, treatment, trial design,
This article reviews a novel Bayesian joint mixed-effects model for analyzing lung function decline and mortality in fibrotic ILD, improving accuracy in estimating disease progression and treatment effects in clinical settings.
An international study found that electronic nose breath analysis can distinguish fibrotic interstitial lung disease subtypes with good accuracy, suggesting a promising noninvasive tool to support diagnosis.
